CClinicalTrials.gg
CompletedNCT02575209Updated Jan 31, 2018

Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects

An observational study in Women With Recent Diagnosis of Schizophrenia, Men With Recent Diagnosis of Schizophrenia and Healthy Women, sponsored by Corporacion Parc Tauli. Completed at 1 site in Spain. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-31.

Sponsored by Corporacion Parc Tauli · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Individuals with schizophrenia have important and persistent deficits in multiple neurocognitive domains as well as in the Social Cognition (SC). SC refers to the mental operations underlying social behavior, and it is understood as a multidimensional construct that comprises emotional processing (EP), social perspective and knowledge, attributional bias and theory of mind (ToM) or mentalizing. Mentalizing and EP skills have been the two most studied subdomains of SC in schizophrenia. Both domains have been found to be impaired in chronic schizophrenia patients as well as in patients in early stages of the illness. In this context, although negative symptoms may play and important role, females seem to perform better than males in ToM and EP tasks, suggesting the presence of gender differences in the SC skills in patients with schizophrenia. However, to our knowledge, there are no studies that have explored the gender-related differences between cognitive and affective ToM and its relationship with the EP performance in schizophrenia patients of recent diagnosis comparing with healthy subjects.

In this line, the main objective of this project is to analyze the influence of gender in the cognitive and affective ToM abilities, in a group of patients with schizophrenia in early stages of the illness comparing with healthy subjects. Secondarily, this study pretends to explore the association between EP skills and affective ToM tasks performance in males and females with and without recent diagnosis of schizophrenia.

Read the detailed description

50 patients (25 men and 25 women) will be recruited to participate in the study. Diagnosis of schizophrenia or schizoaffective disorder will be obtained through the medical records of each patient, and confirmed with the administration of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (American Psychiatric Association, 1994) by an expert psychiatrist. The same professional will confirm the inclusion and exclusion criteria, and administrate and correct the Positive and Negative Syndrome Scale (PANNS) of all patients. An expert neuropsychologist will administrate and correct the the abbreviated form of the Wechsler Adult Intelligence Scale (WAIS-III) and the ToM and EP tasks.

In a second phase, a total of 50 healthy people (25 men and 25 women), matched according to age and years of schooling with the previous group, will be recruited. An expert neuropsychologist will confirm the inclusion and exclusion criteria, and administrate and correct the Vocabulary subtests of the WAIS-III and ToM and EP tasks.

All of them will be informed about the characteristics of the study before participating, and will sign an informed consent approved by the ethical committee of the hospital. The subjects will participate voluntarily.

4 groups ANOVAs will be performed for studying differences in affective and cognitive ToM between the groups (1-Women With Recent Diagnosis of Schizophrenia; 2-Men With Recent Diagnosis of Schizophrenia; 3-Healthy Women; 4-Healthy Men). Linear regression models will be performed for exploring the relationship between gender, negative symptoms (only in the schizophrenia sample) and EP (independents variables) in affective ToM (dependent variable).

02

Conditions studied

  • Women With Recent Diagnosis of Schizophrenia
  • Men With Recent Diagnosis of Schizophrenia
  • Healthy Women
  • Healthy Men
03

In context

Disease

1,327 studies on the registry are indexed under Disease; 596 are open to participants now.

This study's enrollment of 80 is below the median of 210 across 573 observational studies indexed under Disease.

Browse Disease studies →

Lead sponsor

Corporacion Parc Tauli is the lead sponsor of 163 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Females and males with and without schizophrenia of recent diagnosis.

Eligibility criteria

PARTICIPANTS WITH SCHIZOPHRENIA

Inclusion Criteria:

  • Patients meeting DSM-IV criteria for schizophrenia or schizoaffective disorder with less than 5 years of evolution of the disorder.
  • Being an outpatient for at least 4 weeks before the study (clinical stability).
  • No changes in the antipsychotic medication during the month before the study.
  • Score less than 4 in the P1, P2 and P3 items of the PANSS.
  • Score less than 4 in the Calgary Depression Scale.

Exclusion Criteria:

  • Intellectual disability (IQ\<70).
  • History of brain damage.
  • History of substance abuse (except nicotine or caffeine) during the last 12 months before the study.

PARTICIPANTS WITHOUT SCHIZOPHRENIA

Inclusion Criteria:

  • Healthy people over 18 years old.

Exclusion Criteria:

  • Sensory impairment: visual or hearing disabilities.
  • Intellectual disability (IQ\<70).
  • History of neurologic disease.
  • History of psychiatric disorder.
  • History of substance abuse (except nicotine or caffeine) during the last 12 months before the study.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • Women schiz.

    Women with recent diagnosis of schizophrenia

    Other: GENDER

  • Men schiz.

    Men with recent diagnosis of schizophrenia

    Other: GENDER

  • Women healthy

    Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis

    Other: GENDER

  • Men healthy

    Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis

    Other: GENDER

Interventions

  • OtherGENDER
06

What researchers measure

Primary outcomes

  1. Affective Theory of Mind

    Measured by: Reading the Mind in the Eyes test (RMET)

    Time frame: Through study completion, an average of 6 months

  2. Cognitive Theory of Mind

    Measured by: False belief stories

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Emotional Processing

    Measured by: Pictures of Facial Affect (POFA)

    Time frame: Through study completion, an average of 6 months

  2. Psychosis Symptoms

    Measured by: Positive and Negative Syndrome Scale

    Time frame: Through study completion, an average of 6 months

Other outcomes

  1. Intelligence Quotient (IQ) in schizophrenia groups

    Measured by: The abbreviated form of the Wechsler Adult Intelligence Scale (WAIS-III) (Blyder et al., 2000)

    Time frame: Through study completion, an average of 6 months

  2. Intelligence Quotient (IQ) in healthy groups

    Measured by: The Vocabulary subtest (WAIS-III) in healthy participants.

    Time frame: Through study completion, an average of 6 months

07

Study locations

1 site
  • Corporació Parc Taulí
    Sabadell, Barcelona 08208, Spain
08

References and documents

Publications

  • Abu-Akel A, Bo S. Superior mentalizing abilities of female patients with schizophrenia. Psychiatry Res. 2013 Dec 30;210(3):794-9. doi: 10.1016/j.psychres.2013.09.013. Epub 2013 Oct 5. PubMed 24103909 ↗
  • Bora E, Pantelis C. Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophr Res. 2013 Mar;144(1-3):31-6. doi: 10.1016/j.schres.2012.12.013. Epub 2013 Jan 21. PubMed 23347949 ↗
  • Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry. 2011 Feb;45(2):93-108. doi: 10.3109/00048674.2010.541418. PubMed 21320033 ↗
  • Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, Kring AM, Park S, Silverstein SM, Heinssen R. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008 Nov;34(6):1211-20. doi: 10.1093/schbul/sbm145. Epub 2008 Jan 8. PubMed 18184635 ↗
  • Kohler CG, Turner TH, Bilker WB, Brensinger CM, Siegel SJ, Kanes SJ, Gur RE, Gur RC. Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry. 2003 Oct;160(10):1768-74. doi: 10.1176/appi.ajp.160.10.1768. PubMed 14514489 ↗
  • Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009 May;23(3):315-36. doi: 10.1037/a0014708. PubMed 19413446 ↗
  • Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull. 2013 Sep;39(5):979-92. doi: 10.1093/schbul/sbs080. Epub 2012 Sep 4. PubMed 22949733 ↗
  • Navarra-Ventura G, Fernandez-Gonzalo S, Turon M, Pousa E, Palao D, Cardoner N, Jodar M. Gender Differences in Social Cognition: A Cross-Sectional Pilot Study of Recently Diagnosed Patients with Schizophrenia and Healthy Subjects. Can J Psychiatry. 2018 Aug;63(8):538-546. doi: 10.1177/0706743717746661. Epub 2017 Dec 7. PubMed 29216439 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02575209
Lead sponsor
Corporacion Parc Tauli
Responsible party
Sol Fernandez-Gonzalo (Neuropsychologist researcher, Corporacion Parc Tauli) — Principal investigator
First posted
Oct 14, 2015
Start date
Sep 2015
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Jan 31, 2018

Study contacts

Sol Fernandez-Gonzalo, PhD
principal investigator · Corporació Parc Taulí
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion